1. Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting 
Jeffrey Paul Clark, MD, Edward Langston, MD 
Mayo Clinic Proceedings 
Volume 78, Issue 9, Pages (September 2003)
DOI: /
Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
Telithromycin inhibits bacterial protein synthesis by blocking peptidyl transferase activity. rRNA = ribosomal RNA.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Figure 2
Penetration of telithromycin at the site of infection and into bronchopulmonary fluids. Telithromycin concentrations (mg/L or mg/kg) in (A) plasma, (B) bronchial mucosa, (C) epithelial lining fluid, and (D) alveolar macrophages. BLQ = below limit of quantification.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

4. Figure 3
Clinical cure and bacterial eradication rates with telithromycin, arranged by indication. AECB = acute exacerbations of chronic bronchitis; AS = acute sinusitis; CAP = community-acquired pneumonia; T/P = tonsillitis/pharyngitis.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions

5. Figure 4
Activity of telithromycin (800 mg once daily) against infections due to Streptococcus pneumoniae with reduced susceptibility to penicillin (PEN) or erythromycin (ERY); results are from 11 phase 3 clinical trials.85 ERY-R = erythromycin resistant; PEN-I = penicillin intermediate resistance; PEN-R = penicillin resistant. *74 of 81 isolates had a clinical cure; 75 of 81 isolates had a bacterial eradication.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2003 Mayo Foundation for Medical Education and Research Terms and Conditions